A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

Summary

The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection bilaterally every 6 weeks in patients with late-stage retinitis pigmentosa (RP). Late-stage RP patients will include those patients with No Light Perception (NLP), or Low Vision (LV).

Timeline

Start

2025-08-29

Primary completion

2027-08

Completion

2027-08

Drugs

Indications